These findings agree with published reports in that a low level of TGF-βR (both TGF-βRI and TGF- βRII) has been demonstrated to correlate with disease progression [49] and high levels of TGF-β1 in colon cancer have been correlated with a poor disease prognosis in a clinical setting, specifically increasing metastasis and general invasiveness [50, 51]. Here, TGFB1 is linked to malignant colon neoplasm.